The estimated Net Worth of Susanna Gatti High is at least $13 Миллион dollars as of 11 September 2024. Ms High owns over 5,270 units of Dyne Therapeutics stock worth over $4,583,951 and over the last 8 years she sold DYN stock worth over $8,032,641. In addition, she makes $409,310 as Chief Operating Officer at Dyne Therapeutics.
Ms has made over 23 trades of the Dyne Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 5,270 units of DYN stock worth $168,060 on 11 September 2024.
The largest trade she's ever made was selling 85,270 units of Dyne Therapeutics stock on 10 June 2024 worth over $2,583,681. On average, Ms trades about 7,790 units every 75 days since 2016. As of 11 September 2024 she still owns at least 140,612 units of Dyne Therapeutics stock.
You can see the complete history of Ms High stock trades at the bottom of the page.
Susanna Gatti High M.B.A. is the Chief Operating Officer at Dyne Therapeutics.
As the Chief Operating Officer of Dyne Therapeutics, the total compensation of Ms A at Dyne Therapeutics is $409,310. There are 4 executives at Dyne Therapeutics getting paid more, with Dewei Qiao having the highest compensation of $2,036,560.
Ms A is 53, she's been the Chief Operating Officer of Dyne Therapeutics since . There are 7 older and 15 younger executives at Dyne Therapeutics. The oldest executive at Dyne Therapeutics, Inc. is Yuezhou Ou, 68, who is the Independent Non-Executive Director.
Susanna's mailing address filed with the SEC is C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM, MA, 02451.
Over the last 4 years, insiders at Dyne Therapeutics have traded over $197,573,300 worth of Dyne Therapeutics stock and bought 5,790,447 units worth $92,382,301 . The most active insiders traders include Capital Management, L.P.Kol..., Jason P Rhodes и Dirk Kersten. On average, Dyne Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $3,566,016. The most recent stock trade was executed by Oxana Beskrovnaya on 11 September 2024, trading 2,161 units of DYN stock currently worth $68,914.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Dyne Therapeutics executives and other stock owners filed with the SEC include: